Finance

Lists
OVID:NASDAQ
Ovid Therapeutics Inc
$2.17
+0.93%
(+0.020) 1D
$2.17
0.00% (0.00)
After hours
Closed: Oct 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OVID...
Open
$2.18
High
$2.22
Low
$2.14
Mkt. cap
423.80M
Avg. vol.
1.64M
Volume
1.64M
52-wk high
$3.10
52-wk low
$1.18
EPS
-$0.25
Beta
0.22
Shares outstanding
195.30M
No. of employees
23
Open
$2.18
High
$2.22
Low
$2.14
Mkt. cap
423.80M
Avg. vol.
1.64M
Volume
1.64M
52-wk high
$3.10
52-wk low
$1.18
EPS
-$0.25
Beta
0.22
Shares outstanding
195.30M
No. of employees
23
News stories
From web sources and news partners
About Ovid Therapeutics Inc
CEO-
Employees23
Founded2014
Headquarters-
SectorBiotechnology
Websiteovidrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to OVID in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for OVID in the last 3 months.
Highest
Current $2.17
$9.00 (+314.75%)
Average
$6.50 (+199.54%)
Lowest
$5.00 (+130.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Rudy Li
Wolfe Research
Buy
Initiated
$5.00
+130.4%
10/15/2026
Imogen Mansfield
Cantor Fitzgerald
Buy
Initiated
$6.00
+176.5%
10/09/2026
Laura Chico
Wedbush
Buy
Maintained
$7.00
+222.6%
10/08/2026
Delma Caiati
Guggenheim
Buy
Initiated
$7.00
+222.6%
10/05/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$7.00
+222.6%
10/05/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$5.00
+130.4%
09/11/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Maintained
$8.00
+268.7%
09/03/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$5.00
+130.4%
08/14/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$9.00
+314.7%
08/14/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/13/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
08/13/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
$5.00
+130.4%
05/13/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
$5.00
+130.4%
05/13/2026
Thomas Shrader
BTIG
Buy
Maintained
$4.00
+84.3%
03/26/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
-$0.08 / -$0.10
+23.29%beat
Revenue / Est. (USD)
733.00K / 0.00
+∞%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
132.00K
718.00K
-
733.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.87M
6.59M
11.18M
9.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.78M
6.42M
6.66M
6.17M
Operating expense
12.66M
13.01M
17.85M
16.13M
Total operating expenses
12.66M
13.01M
17.85M
16.13M
Operating income
-12.52M
-12.29M
-17.85M
-15.40M
Other non operating income
62.00K
57.00K
121.00K
-869.00K
EBT including unusual items
-12.16M
9.66M
-16.99M
-15.01M
EBT excluding unusual items
-12.16M
-11.39M
-16.99M
-14.71M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.16M
9.66M
-16.99M
-15.01M
Net profit margin
-9,210.61%
1,345.82%
-
-2,047.61%
Earnings per share
-0.17
0.06
-0.12
-0.08
Interest and investment income
303.00K
847.00K
737.00K
1.56M
Interest expense
-
-
-
-
Net interest expenses
303.00K
847.00K
737.00K
1.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.51M
-12.28M
-17.81M
-15.38M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps